Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers

A FSTL1, tissue fibrosis technology, applied in the field of anti-fibrotic homeostasis regulation and anti-right ventricular dilation drugs, can solve the problem that the pulmonary arterial hypertension model has not been widely used and so on

Active Publication Date: 2017-08-15
何玉龙
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have shown that FSTL1 is associated with abnormal vascular remodeling leading to right heart dilated lesions
At present, in biomedical experiments, the experimental methods for establishing pulmonary hypertension mainly include chronic hypoxia, monocrotaline injection, shunt surgery, etc. However, the pulmonary hypertension model established by gene knockout technology has not been widely used

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers
  • Protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers
  • Protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Establishment of vascular endothelial cell-specific Fstl1 knockout mouse model

[0065] with Fstl1 + / - Mice (B6 background, provided by Nanjing Animal Model Institute) were mated with Tek-cre mice to obtain Fstl1 + / - , Tek-cre mice, and then use this mouse with Fstl1 Flox / Flox Mice mated to Fstl1 Flox / - , Tek-cre, this mouse is used as experimental mouse (also known as Fstl1 in the present invention - / ECKO ), using littermate gene knockout heterozygous (also known as Fstl1 - / WT ) or wild mice (also known as Fstl1 WT / WT ) as a control mouse.

[0066] Take fresh mouse liver, lung and kidney tissues, wash them in PBS, freeze them quickly in liquid nitrogen, and store them in a -80°C freezer for RNA extraction and protein preparation; the rest of the tissues were fixed overnight in 4% PFA , Tissue embedding and sectioning were performed by conventional histological methods for histological analysis. The knockout efficiency of Fstl1 was detected by Western B...

Embodiment 2

[0067] Example 2 Establishment of a mouse model for systemic inducible Fstl1 gene knockout

[0068] with Fstl1 + / - Mice mated with transgenic mice expressing UBC-CreERT2 to obtain Fstl1 + / - ; UBC-Cre / ERT2 mice, and then use this mouse with Fstl1 Flox / Flox Mice mated to Fstl1 Flox / - ; UBC-Cre / ERT2 (also referred to as Fstl1 in the present invention - / iKO ), this genotype mouse was used as an experimental mouse, and the Fstl1 obtained at the same time Flox / + ; UBC-Cre / ERT2 as a control mouse (Control).

[0069] Mice can induce Fstl1 gene knockout at different stages after birth, including neonatal mice (birth day 1-4, P1-P4), and different stages of growth and development, including adult mice, to produce liver fibrosis that can simulate clinical human occurred in animal models. The preparation method of the mouse Fstl1 gene-induced knockout model is as follows:

[0070] After the mice were born (days 1-4, P1-P4), the mice were injected with tamoxifen (60ug per mouse) thr...

Embodiment 3

[0071] Example 3 Vascular endothelial cell-specific Fstl1 knockout mouse liver fibrotic disease model

[0072] In the process of liver fibrosis, extracellular matrix mainly composed of collagen accumulates in large quantities. Three weeks after birth, liver tissues were taken from mice and fixed in 4% paraformaldehyde PFA for 2 hours, then incubated overnight in 20% sucrose solution, and then tissue-embedded and sectioned, and stained with Sirius red. The specific method is briefly described as follows : Take Sirius red dye Sirius red (purchased from Sigma company) 0.5g, dissolve in 500mL of picric acid (purchased from Shanghai Sangong, product number PB0716), and store at room temperature until use. Using Sirius red staining analysis, it was found that knocking out Fstl1 in vascular endothelial cells led to a significant increase in collagen content in liver tissue ( Figure 4 , red represents Sirius red staining of collagen in the liver). In addition, hydroxyproline is a m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers, and particularly relates to uses of FSTL1 protein or an FSTL1 regulating compound in preparation of medicines treating tissue fibrosis diseases. The invention also relates to a conditional FSTL1 gene knockout non-human animal model closely related to the degree of tissue fibrosis pathological changes, a preparing method thereof and uses of the model in tissue-fibrosis-preventing medicine screening. Treatment is performed by combining different tamoxifen dosages and different animal growth stages, the systemic or vascular endothelial cell FSTL1 gene knockout non-human animal model is obtained and the model is used for simulating different tissue fibrosis pathological changes.

Description

technical field [0001] Use of the FSTL1 protein or its regulating compound of the present invention in the preparation of medicines for anti-fibrosis homeostasis regulation and anti-right ventricle expansion in tissues and organs such as liver, lung, and kidney. The present invention also relates to a non-human transgenic animal model and its construction method and application, in particular to a controllable follistatin-like protein 1 (FSTL1) gene induced by different doses of tamoxifen at different growth stages of animals Conditional knockout transgenic mouse animal model, its construction method and its application in tissue fibrosis. Background technique [0002] Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein originally cloned from the mouse osteoblast cell line MC3T3, which is expressed in a variety of cells except blood cells, especially in mesenchymal lines Higher expression level in cells (Knight, C., et al., J Dent Res, 2001.80(10): p.1895-902; Gen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K49/00A61P1/16A61P11/00A61P13/12A61P9/00A01K67/027A01K67/02
CPCA01K67/0276A01K2217/075A01K2217/15A01K2227/105A01K2267/03A01K2267/0375A61K49/0008C07K14/575C12N15/85C12N2800/107C12N2800/30
Inventor 何玉龙蒋海娟张禄卿
Owner 何玉龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com